INOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
Rhea-AI Summary
INOVIO (NASDAQ:INO) will release fourth quarter and full year 2025 financial results after market close on March 12, 2026.
Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss results and provide a general business update; the webcast will be archived for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – INO
In the Mar 6 session, INO gained 3.57%, reflecting a moderate positive market reaction. Argus tracked a trough of -2.8% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| 2026-03-04 | Clinical collaboration | Positive | +3.0% | Announced Phase 2 INSIGhT trial combo for glioblastoma with Akeso. |
| 2026-02-12 | Conference participation | Positive | -1.9% | Outlined upcoming scientific and investor conference presentations and meetings. |
| 2025-12-29 | Regulatory update | Negative | -24.4% | FDA accepted INO-3107 BLA and highlighted an accelerated approval review issue. |
| 2025-12-19 | Inducement grant | Neutral | -1.3% | Reported equity inducement option grant to a new employee under plan. |
| 2025-11-18 | Investor conferences | Positive | -4.5% | Planned December investor conference appearances and one-on-one meetings. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent INOVIO news has often seen muted to negative price reactions, with one notably sharp decline following FDA BLA review details.
Over the past several months, INOVIO has reported multiple corporate and clinical milestones. A clinical collaboration for glioblastoma was followed by a 2.98% gain, while conference participation and an inducement grant saw modest declines. The FDA’s acceptance of the INO-3107 BLA, which included a potential review issue, coincided with a -24.45% move. Against this backdrop, today’s announcement of the March 12, 2026 earnings release date fits into a steady cadence of updates spanning clinical, regulatory, and corporate activities.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The live webcast will be available online at http://ir.inovio.com/events-and-presentations/default.aspx. This is a listen-only event but will include a live Q&A with analysts. The webcast will be archived and available for replay for 90 days following the event.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancers, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, investor.relations@inovio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026-302705847.html
SOURCE INOVIO Pharmaceuticals, Inc.